Synonyms: Compound A [WO2022119905A2]
Compound class:
Synthetic organic
Comment: Uplarafenib is the INN for a BRAF inhibitor that was designed as an antineoplastic agent. It is one of the compounds claimed in patent WO2022119905A2 (NeuPharma) [1]. Uplarafenib is likely Henlius/NeuPharma lead BRAF asset HLX208 (RX208), that is designed to target oncogenic BRAFV600E.
|
|
Bioactivity Comments |
Information provided in WO2022119905A2 suggests that this compound has inhibitor activity across a range of kinases, inlcuding ARAF, BRAF (including mutants), CRAF-1, Fak, FGFR1-4, Jnk1-13, Lek, Lyn, Met, Pim1-3, Pyk2, KDR, Src and Ret with pM-nM potencies [1]. It appears to be most potent against BRAF and BRAF mutants (BRAFV600E, BRAFV600E/T5291). |